Hematologic Malignancy
Splenic Marginal Zone Lymphoma
CI-CAN-00006828SLVL · SMZLExplore in graph →
Hematologic11 active trials
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006828SLVL · SMZLExplore in graph →
Clinical trials
135 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (32)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07759661 | Innovative 3D Preclinical Models for Mature B-cell Malignancies to Advance Personalized Immuno and Combination Therapies(IMPACT) | not yet recruiting | — | 64 | IRCCS San RaffaeleOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07638722 | Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment | not yet recruiting | Phase 2 | 138 | SWOG Cancer Research NetworkNETWORK |
| 0 |
| Jul 13, 2026 |
| clinicaltrials |
Data updated 23 days agoSource updated Aug 13, 2026source: clinicaltrials